CalciMedica sets mid-2027 targets for PH data and CM5480 IND, cash runs into H2 2027

CalciMedica reported third quarter 2026 results on November 10, 2026, alongside pipeline updates for its CRAC channel inhibitor programs. The company plans to test Auxora in a Phase 1b trial in pulmonary hypertension patients, aiming to produce early clinical evidence of how CRAC channel inhibition affects cardiac and pulmonary function.¹ Trial design details and the target patient population are expected by the end of the year, with data anticipated in mid-2027.¹

The company is also continuing preclinical and IND-enabling work on CM5480, its oral CRAC channel inhibitor intended for chronic use in pulmonary hypertension, with data suggesting the compound may protect right ventricular function, and an IND submission anticipated in mid-2027.¹

In acute pancreatitis, CalciMedica said FDA aligned in July, following a Type C meeting, with the company's Phase 2b trial design, which will test whether enrollment based on elevated lactate dehydrogenase levels selects for more severe outcomes, using severe respiratory failure as the primary endpoint.¹ Initiation of that trial depends on additional financing.¹

On the corporate side, CalciMedica completed a 1-for-5 reverse stock split effective August 31, 2026, cutting shares outstanding from about 34.5 million to about 6.9 million and bringing the company into compliance with Nasdaq's minimum bid price rule.¹

Cash, cash equivalents and short-term investments stood at $13.8 million as of September 30, 2026, which the company said is expected to fund its current operating plan into the second half of 2027.¹ Net loss for the quarter was $1.7 million, which included a noncash $3.1 million gain in other income, compared with a $7.8 million net loss in the same period of 2025.¹